| Name | Title | Contact Details |
|---|
Broadpoint Gleacher Securities Group Inc, formerly Broadpoint Securities Group Inc, is an independent investment bank that provides value-added advice to corporations and institutional investors.
Ferguson Wellman Capital Management, Inc. is one of the leading companies in the Financial Services sector.
The Riverside Company is a global private equity firm focused on making control and non-control investments in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has invested in more than 430 transactions. The firm`s international portfolio includes more than 80 companies.
WisdomTree Investments, Inc. through its subsidiaries in the U.S. and Europe (collectively, “WisdomTree”), is an ETF and ETP sponsor and asset manager headquartered in New York. WisdomTree offers products covering equity, commodity, fixed income, leveraged and inverse, currency, cryptocurrency and alternative strategies. WisdomTree currently has approximately $74.0 billion in assets under management globally.
Harris and Harris Group, Inc. builds transformative companies from disruptive science. We leverage our core scientific expertise to be FIRST in identifying new technology trends, in accessing high quality science and intellectual property, in building management teams and in executing on early-stage business growth. Our PROVEN team has the unique ability to identify and diligence the network of discoveries that come from understanding science at the intersection of different scientific disciplines, with biology as a focus. This places us at the center of the discoveries impacting some of the most important growth sectors of the economy, permitting us to build TRANSFORMATIVE companies. BIOLOGY+ is our distinctive approach. We define BIOLOGY+ as investments in interdisciplinary life science companies where biology innovation is intersecting with innovations in areas such as electronics, physics, materials science, chemistry, information technology, engineering and mathematics. We focus on this intersection because we believe interdisciplinary innovation will be required in order to address many of the life science challenges of the future.